Viewing Study NCT05781035



Ignite Creation Date: 2024-05-06 @ 6:46 PM
Last Modification Date: 2024-10-26 @ 2:54 PM
Study NCT ID: NCT05781035
Status: COMPLETED
Last Update Posted: 2023-10-25
First Post: 2023-02-23

Brief Title: Dexmedetomidine Versus General Anesthesia on the Diagnosis of Endobronchial US-Guided Transbronchial Needle Aspiration
Sponsor: Kafrelsheikh University
Organization: Kafrelsheikh University

Study Overview

Official Title: Moderate Sedation by Dexmedetomidine Versus General Anesthesia on the Diagnostic Yield of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration A Randomized Controlled Study
Status: COMPLETED
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of this study is to compare dexmedetomidine as moderate sedation versus general anathesia on the diagnostic yield of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Detailed Description: Endobronchial ultrasound EBUS-guided transbronchial needle aspiration EBUS-TBNA has emerged as a highly effective minimally invasive technique for sampling peribronchial mediastinal and lung masses for pathologic examination with low rate of complications and costs

Dexmedetomidine is a high-affinity adrenergic agonist of the alpha 2 receptor is a potential alternative sedative

The use of dexmedetomidine does not lead to respiratory depression or to a decline in cognitive skills or patient cooperation This is because dexmedetomidine acts on the alpha-2 receptors in the locus coeruleus in contrast to other sedatives midazolam and propofol which act on GABA receptorscerebral cortex

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None